Welcome to our dedicated page for Electromed SEC filings (Ticker: ELMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Electromed's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Electromed's regulatory disclosures and financial reporting.
Electromed, Inc. Chief Financial Officer Bradley M. Nagel reported a small share disposition related to taxes, not an open-market trade. On the reported date, 674 shares of common stock were forfeited at $42.30 per share to cover tax withholding when previously awarded restricted stock vested. After this tax-withholding event, Nagel directly held 18,964 shares of Electromed common stock, indicating the transaction was routine and left his overall ownership largely unchanged.
Electromed, Inc. CEO and President James L. Cunniff reported a combination of stock sales and an option exercise involving the company’s common stock. On June 8, 2026, he sold a total of 9,700 shares in three open-market transactions at weighted average prices of $37.7729, $36.7975, and $36.2490 per share. The same day, he exercised employee stock options to acquire 9,700 shares at an exercise price of $17.25 per share. Following these transactions, he directly holds 147,751 shares of Electromed common stock.
Electromed, Inc.’s Chief Financial Officer, Bradley M. Nagel, reported a combination of stock option exercises and share sales on June 4, 2026. He exercised options to acquire 9,601 shares of common stock at exercise prices of $10.71 and $10.25 per share, converting derivative awards into common shares.
On the same date, he sold a total of 11,801 common shares in open-market transactions, with weighted average sale prices of approximately $36.34 for 11,620 shares and $37.11 for 181 shares. After these exercises, he retained 2,633 options at an exercise price of $10.71 expiring on June 30, 2033 and 2,166 options at $10.25 expiring on November 10, 2033.
ELMD filed a Form 144 reporting proposed sales of Common Stock. The notice lists 06/30/2024 entry of 2,200 shares described as "Restricted Stock Vesting" and a 06/04/2026 entry of 9,601 shares described as "Stock Option Exercise" with Cash indicated. The broker shown is Fidelity Brokerage Services LLC at 900 Salem Street, Smithfield, RI, and the trading venue is listed as NYSE American.
Electromed, Inc. director Kathleen Skarvan reported a combination of option exercises and share sales. On May 15, 2026, she exercised employee stock options for 40,000 shares of common stock at an exercise price of $3.82 per share.
The filing also shows four open-market sales totaling 40,000 shares of common stock on the same date, at weighted average prices of $37.33, $36.258, $35.2422, and $34.3626 per share, each executed in multiple transactions within stated price ranges. The options exercised were fully vested and related derivative positions were exhausted.
Electromed, Inc. delivered strong results for the quarter ended March 31, 2026, with net revenues of $18.6 million, up 18.4% from $15.7 million a year earlier. Growth was led by homecare sales and faster expansion in the hospital market.
Quarterly net income rose to $3.0 million from $1.9 million, while diluted EPS increased to $0.35 from $0.21, reflecting higher volumes and improved net revenues per device. Gross margin remained high at about 79%, helping operating income grow faster than sales.
The company ended the period with $17.0 million in cash and no borrowings on its $10 million revolving credit facility, and has active share repurchases, having bought back 151,911 shares for $3.9 million under a $10 million authorization.
Electromed, Inc. reported record results for its fiscal Q3 ended March 31, 2026, with net revenues of $18.6 million, up 18.4% from $15.7 million a year earlier. Growth was driven mainly by its direct homecare business, where revenue rose 18.6% to $16.7 million on more sales reps, higher productivity, and greater revenue per representative.
Gross profit increased to $14.6 million, with gross margin improving to 78.8%. Operating income jumped 76.0% to $3.8 million, lifting operating margin to 20.3%. Net income grew 58.8% to $3.0 million, or $0.35 per diluted share, compared with $0.21.
The company ended the quarter with $17.0 million in cash, no debt, working capital of $40.0 million and shareholders’ equity of $49.2 million. Over the nine-month period, Electromed generated $6.7 million in operating cash flow while repurchasing $3.9 million of its common stock.
Electromed Inc: The Vanguard Group filed an Amendment No. 1 to Schedule 13G reporting beneficial ownership of 0 shares (0%) of Common Stock. The filing states Vanguard completed an internal realignment on January 12, 2026 and will report certain subsidiaries separately "in accordance with SEC Release No. 34-39538 (January 12, 1998)".
The amendment lists Vanguard's address and shows no sole or shared voting or dispositive power over Electromed shares. The signature block is by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.